COMP <GO>
GEHC vs MRK // EV/EBITDA & P/E VALUATION
GE HealthCare Technologies Inc. Common Stock (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: GEHC 7
— MRK 8
▲ EV/EBITDA & P/E VALUATION LEADER: GEHC
LAST: $76.57 (+0.20%) • MKT CAP: $34.55B
valuation
11.1x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GEHC VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GEHC | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 40.00% | 74.80% | -34.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.20% | 20.70% | -6.50 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 11.1x | 15.3x | -4.20 | GEHC | /valuation <GO> |
| Free Cash Flow Yield | 4.19% | 3.42% | +0.77 | GEHC | /fcf-yield <GO> |
| Operating Margin | 13.40% | 34.30% | -20.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | 10.10% | 28.10% | -18.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 4.80% | 1.30% | +3.50 | GEHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.19% | 2.26% | -2.07 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.90 | 5.19 | -3.29 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | GEHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.60% | +0.80 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 74.1 | 56.9 | +17.24 | GEHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.92 | +0.23 | GEHC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.4x | 18.4x | -3.00 | GEHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $34.55B | $361.02B | -$326.47B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GEHC REV | MRK REV | GEHC GROSS % | MRK GROSS % | GEHC FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.63B | $65.01B | 40.0% | 74.8% | $1.41B | $12.36B |
| FY 2024 | $19.67B | $64.17B | 41.7% | 76.3% | $1.35B | $18.10B |
| FY 2023 | $19.55B | $60.12B | 44.0% | 44.0% | $876.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GEHC // BETA 1.15
MRK // BETA 0.92